Clinical Trial Update: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis [Phase 1, Phase 2]

View source ↗

Summary

The document reports on the safety, tolerability, and immunogenic response of the investigational CV-MG01 in patients with Myasthenia gravis in Phase 1/Phase 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• CV-MG01

Snippet

Sponsor: CuraVac | Conditions: Myasthenia Gravis | Phase 1, Phase 2 | Status: COMPLETED